ON 4 DECEMBER 2013, THE HIGH COURT JUDGMENT IN APOTEX PTY LTD V SANOFI-AVENTIS AUSTRALIA PTY LTD & ORS  HCA 50 WAS DELIVERED. THIS IS THE FIRST OCCASION THAT THE HIGH COURT HAS CONSIDERED WHETHER METHODS OF MEDICAL TREATMENT OF THE HUMAN BODY ARE PATENTABLE INVENTIONS WITHIN THE MEANING OF SECTION 18(1) OF THE PATENTS ACT 1990 (CTH). THE MAJORITY OF THE HIGH COURT CONCLUDED THEY WERE, WHILST PROVIDING IMPORTANT GUIDANCE ON CONTRIBUTORY (OR INDIRECT) INFRINGEMENT IN THE CONTEXT OF PATENTS WHICH CLAIM METHODS OF MEDICAL TREATMENT.
SUMMARY OF THE MATTER -
Parties and the patent -
By way of background, the patent in issue was Australian Patent No 670491, entitled Pharmaceutical for the treatment of skin disorders. Relevantly, the patent claims:
[a] method of preventing or treating a skin disorder wherein the skin disorder is psoriasis, which comprises administering to a recipient an effective amount of [leflunomide].
Sanofi-Aventis Australia Pty Ltd (Sanofi) markets leflunomide in Australia under the brand name ARAVA®.
Please see full alert below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.